for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Oxford University Press   (Total: 396 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 396 Journals sorted alphabetically
ACS Symposium Series     Full-text available via subscription   (SJR: 0.189, CiteScore: 0)
Acta Biochimica et Biophysica Sinica     Hybrid Journal   (Followers: 5, SJR: 0.79, CiteScore: 2)
Adaptation     Hybrid Journal   (Followers: 9, SJR: 0.143, CiteScore: 0)
Advances in Nutrition     Hybrid Journal   (Followers: 46, SJR: 2.196, CiteScore: 5)
Aesthetic Surgery J.     Hybrid Journal   (Followers: 6, SJR: 1.434, CiteScore: 1)
African Affairs     Hybrid Journal   (Followers: 64, SJR: 1.869, CiteScore: 2)
Age and Ageing     Hybrid Journal   (Followers: 91, SJR: 1.989, CiteScore: 4)
Alcohol and Alcoholism     Hybrid Journal   (Followers: 18, SJR: 1.376, CiteScore: 3)
American Entomologist     Full-text available via subscription   (Followers: 7)
American Historical Review     Hybrid Journal   (Followers: 154, SJR: 0.467, CiteScore: 1)
American J. of Agricultural Economics     Hybrid Journal   (Followers: 41, SJR: 2.113, CiteScore: 3)
American J. of Clinical Nutrition     Hybrid Journal   (Followers: 147, SJR: 3.438, CiteScore: 6)
American J. of Epidemiology     Hybrid Journal   (Followers: 175, SJR: 2.713, CiteScore: 3)
American J. of Hypertension     Hybrid Journal   (Followers: 25, SJR: 1.322, CiteScore: 3)
American J. of Jurisprudence     Hybrid Journal   (Followers: 18, SJR: 0.281, CiteScore: 1)
American J. of Legal History     Full-text available via subscription   (Followers: 8, SJR: 0.116, CiteScore: 0)
American Law and Economics Review     Hybrid Journal   (Followers: 27, SJR: 1.053, CiteScore: 1)
American Literary History     Hybrid Journal   (Followers: 15, SJR: 0.391, CiteScore: 0)
Analysis     Hybrid Journal   (Followers: 21, SJR: 1.038, CiteScore: 1)
Animal Frontiers     Hybrid Journal  
Annals of Behavioral Medicine     Hybrid Journal   (Followers: 15, SJR: 1.423, CiteScore: 3)
Annals of Botany     Hybrid Journal   (Followers: 36, SJR: 1.721, CiteScore: 4)
Annals of Oncology     Hybrid Journal   (Followers: 42, SJR: 5.599, CiteScore: 9)
Annals of the Entomological Society of America     Full-text available via subscription   (Followers: 10, SJR: 0.722, CiteScore: 1)
Annals of Work Exposures and Health     Hybrid Journal   (Followers: 32, SJR: 0.728, CiteScore: 2)
AoB Plants     Open Access   (Followers: 4, SJR: 1.28, CiteScore: 3)
Applied Economic Perspectives and Policy     Hybrid Journal   (Followers: 18, SJR: 0.858, CiteScore: 2)
Applied Linguistics     Hybrid Journal   (Followers: 56, SJR: 2.987, CiteScore: 3)
Applied Mathematics Research eXpress     Hybrid Journal   (Followers: 1, SJR: 1.241, CiteScore: 1)
Arbitration Intl.     Full-text available via subscription   (Followers: 20)
Arbitration Law Reports and Review     Hybrid Journal   (Followers: 14)
Archives of Clinical Neuropsychology     Hybrid Journal   (Followers: 30, SJR: 0.731, CiteScore: 2)
Aristotelian Society Supplementary Volume     Hybrid Journal   (Followers: 3)
Arthropod Management Tests     Hybrid Journal   (Followers: 2)
Astronomy & Geophysics     Hybrid Journal   (Followers: 43, SJR: 0.146, CiteScore: 0)
Behavioral Ecology     Hybrid Journal   (Followers: 52, SJR: 1.871, CiteScore: 3)
Bioinformatics     Hybrid Journal   (Followers: 303, SJR: 6.14, CiteScore: 8)
Biology Methods and Protocols     Hybrid Journal  
Biology of Reproduction     Full-text available via subscription   (Followers: 10, SJR: 1.446, CiteScore: 3)
Biometrika     Hybrid Journal   (Followers: 20, SJR: 3.485, CiteScore: 2)
BioScience     Hybrid Journal   (Followers: 29, SJR: 2.754, CiteScore: 4)
Bioscience Horizons : The National Undergraduate Research J.     Open Access   (Followers: 1, SJR: 0.146, CiteScore: 0)
Biostatistics     Hybrid Journal   (Followers: 17, SJR: 1.553, CiteScore: 2)
BJA : British J. of Anaesthesia     Hybrid Journal   (Followers: 168, SJR: 2.115, CiteScore: 3)
BJA Education     Hybrid Journal   (Followers: 64)
Brain     Hybrid Journal   (Followers: 68, SJR: 5.858, CiteScore: 7)
Briefings in Bioinformatics     Hybrid Journal   (Followers: 49, SJR: 2.505, CiteScore: 5)
Briefings in Functional Genomics     Hybrid Journal   (Followers: 3, SJR: 2.15, CiteScore: 3)
British J. for the Philosophy of Science     Hybrid Journal   (Followers: 35, SJR: 2.161, CiteScore: 2)
British J. of Aesthetics     Hybrid Journal   (Followers: 26, SJR: 0.508, CiteScore: 1)
British J. of Criminology     Hybrid Journal   (Followers: 585, SJR: 1.828, CiteScore: 3)
British J. of Social Work     Hybrid Journal   (Followers: 88, SJR: 1.019, CiteScore: 2)
British Medical Bulletin     Hybrid Journal   (Followers: 7, SJR: 1.355, CiteScore: 3)
British Yearbook of Intl. Law     Hybrid Journal   (Followers: 32)
Bulletin of the London Mathematical Society     Hybrid Journal   (Followers: 4, SJR: 1.376, CiteScore: 1)
Cambridge J. of Economics     Hybrid Journal   (Followers: 62, SJR: 0.764, CiteScore: 2)
Cambridge J. of Regions, Economy and Society     Hybrid Journal   (Followers: 11, SJR: 2.438, CiteScore: 4)
Cambridge Quarterly     Hybrid Journal   (Followers: 9, SJR: 0.104, CiteScore: 0)
Capital Markets Law J.     Hybrid Journal   (Followers: 2, SJR: 0.222, CiteScore: 0)
Carcinogenesis     Hybrid Journal   (Followers: 2, SJR: 2.135, CiteScore: 5)
Cardiovascular Research     Hybrid Journal   (Followers: 14, SJR: 3.002, CiteScore: 5)
Cerebral Cortex     Hybrid Journal   (Followers: 45, SJR: 3.892, CiteScore: 6)
CESifo Economic Studies     Hybrid Journal   (Followers: 17, SJR: 0.483, CiteScore: 1)
Chemical Senses     Hybrid Journal   (Followers: 1, SJR: 1.42, CiteScore: 3)
Children and Schools     Hybrid Journal   (Followers: 5, SJR: 0.246, CiteScore: 0)
Chinese J. of Comparative Law     Hybrid Journal   (Followers: 4, SJR: 0.412, CiteScore: 0)
Chinese J. of Intl. Law     Hybrid Journal   (Followers: 23, SJR: 0.329, CiteScore: 0)
Chinese J. of Intl. Politics     Hybrid Journal   (Followers: 9, SJR: 1.392, CiteScore: 2)
Christian Bioethics: Non-Ecumenical Studies in Medical Morality     Hybrid Journal   (Followers: 10, SJR: 0.183, CiteScore: 0)
Classical Receptions J.     Hybrid Journal   (Followers: 26, SJR: 0.123, CiteScore: 0)
Clean Energy     Open Access   (Followers: 1)
Clinical Infectious Diseases     Hybrid Journal   (Followers: 65, SJR: 5.051, CiteScore: 5)
Clinical Kidney J.     Open Access   (Followers: 3, SJR: 1.163, CiteScore: 2)
Communication Theory     Hybrid Journal   (Followers: 22, SJR: 2.424, CiteScore: 3)
Communication, Culture & Critique     Hybrid Journal   (Followers: 26, SJR: 0.222, CiteScore: 1)
Community Development J.     Hybrid Journal   (Followers: 27, SJR: 0.268, CiteScore: 1)
Computer J.     Hybrid Journal   (Followers: 9, SJR: 0.319, CiteScore: 1)
Conservation Physiology     Open Access   (Followers: 2, SJR: 1.818, CiteScore: 3)
Contemporary Women's Writing     Hybrid Journal   (Followers: 9, SJR: 0.121, CiteScore: 0)
Contributions to Political Economy     Hybrid Journal   (Followers: 5, SJR: 0.906, CiteScore: 1)
Critical Values     Full-text available via subscription  
Current Developments in Nutrition     Open Access   (Followers: 1)
Current Legal Problems     Hybrid Journal   (Followers: 27)
Current Zoology     Full-text available via subscription   (Followers: 2, SJR: 1.164, CiteScore: 2)
Database : The J. of Biological Databases and Curation     Open Access   (Followers: 8, SJR: 1.791, CiteScore: 3)
Digital Scholarship in the Humanities     Hybrid Journal   (Followers: 14, SJR: 0.259, CiteScore: 1)
Diplomatic History     Hybrid Journal   (Followers: 20, SJR: 0.45, CiteScore: 1)
DNA Research     Open Access   (Followers: 5, SJR: 2.866, CiteScore: 6)
Dynamics and Statistics of the Climate System     Open Access   (Followers: 4)
Early Music     Hybrid Journal   (Followers: 15, SJR: 0.139, CiteScore: 0)
Economic Policy     Hybrid Journal   (Followers: 39, SJR: 3.584, CiteScore: 3)
ELT J.     Hybrid Journal   (Followers: 24, SJR: 0.942, CiteScore: 1)
English Historical Review     Hybrid Journal   (Followers: 52, SJR: 0.612, CiteScore: 1)
English: J. of the English Association     Hybrid Journal   (Followers: 14, SJR: 0.1, CiteScore: 0)
Environmental Entomology     Full-text available via subscription   (Followers: 11, SJR: 0.818, CiteScore: 2)
Environmental Epigenetics     Open Access   (Followers: 3)
Environmental History     Hybrid Journal   (Followers: 27, SJR: 0.408, CiteScore: 1)
EP-Europace     Hybrid Journal   (Followers: 2, SJR: 2.748, CiteScore: 4)
Epidemiologic Reviews     Hybrid Journal   (Followers: 9, SJR: 4.505, CiteScore: 8)
ESHRE Monographs     Hybrid Journal  
Essays in Criticism     Hybrid Journal   (Followers: 17, SJR: 0.113, CiteScore: 0)
European Heart J.     Hybrid Journal   (Followers: 57, SJR: 9.315, CiteScore: 9)
European Heart J. - Cardiovascular Imaging     Hybrid Journal   (Followers: 9, SJR: 3.625, CiteScore: 3)
European Heart J. - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 1)
European Heart J. - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart J. : Case Reports     Open Access  
European Heart J. Supplements     Hybrid Journal   (Followers: 8, SJR: 0.223, CiteScore: 0)
European J. of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9, SJR: 1.681, CiteScore: 2)
European J. of Intl. Law     Hybrid Journal   (Followers: 186, SJR: 0.694, CiteScore: 1)
European J. of Orthodontics     Hybrid Journal   (Followers: 4, SJR: 1.279, CiteScore: 2)
European J. of Public Health     Hybrid Journal   (Followers: 20, SJR: 1.36, CiteScore: 2)
European Review of Agricultural Economics     Hybrid Journal   (Followers: 10, SJR: 1.172, CiteScore: 2)
European Review of Economic History     Hybrid Journal   (Followers: 29, SJR: 0.702, CiteScore: 1)
European Sociological Review     Hybrid Journal   (Followers: 40, SJR: 2.728, CiteScore: 3)
Evolution, Medicine, and Public Health     Open Access   (Followers: 11)
Family Practice     Hybrid Journal   (Followers: 15, SJR: 1.018, CiteScore: 2)
Fems Microbiology Ecology     Hybrid Journal   (Followers: 12, SJR: 1.492, CiteScore: 4)
Fems Microbiology Letters     Hybrid Journal   (Followers: 24, SJR: 0.79, CiteScore: 2)
Fems Microbiology Reviews     Hybrid Journal   (Followers: 30, SJR: 7.063, CiteScore: 13)
Fems Yeast Research     Hybrid Journal   (Followers: 14, SJR: 1.308, CiteScore: 3)
Food Quality and Safety     Open Access   (Followers: 1)
Foreign Policy Analysis     Hybrid Journal   (Followers: 23, SJR: 1.425, CiteScore: 1)
Forest Science     Hybrid Journal   (Followers: 7, SJR: 0.89, CiteScore: 2)
Forestry: An Intl. J. of Forest Research     Hybrid Journal   (Followers: 16, SJR: 1.133, CiteScore: 3)
Forum for Modern Language Studies     Hybrid Journal   (Followers: 6, SJR: 0.104, CiteScore: 0)
French History     Hybrid Journal   (Followers: 33, SJR: 0.118, CiteScore: 0)
French Studies     Hybrid Journal   (Followers: 20, SJR: 0.148, CiteScore: 0)
French Studies Bulletin     Hybrid Journal   (Followers: 10, SJR: 0.152, CiteScore: 0)
Gastroenterology Report     Open Access   (Followers: 2)
Genome Biology and Evolution     Open Access   (Followers: 12, SJR: 2.578, CiteScore: 4)
Geophysical J. Intl.     Hybrid Journal   (Followers: 35, SJR: 1.506, CiteScore: 3)
German History     Hybrid Journal   (Followers: 22, SJR: 0.161, CiteScore: 0)
GigaScience     Open Access   (Followers: 4, SJR: 5.022, CiteScore: 7)
Global Summitry     Hybrid Journal   (Followers: 1)
Glycobiology     Hybrid Journal   (Followers: 14, SJR: 1.493, CiteScore: 3)
Health and Social Work     Hybrid Journal   (Followers: 56, SJR: 0.388, CiteScore: 1)
Health Education Research     Hybrid Journal   (Followers: 15, SJR: 0.854, CiteScore: 2)
Health Policy and Planning     Hybrid Journal   (Followers: 24, SJR: 1.512, CiteScore: 2)
Health Promotion Intl.     Hybrid Journal   (Followers: 22, SJR: 0.812, CiteScore: 2)
History Workshop J.     Hybrid Journal   (Followers: 31, SJR: 1.278, CiteScore: 1)
Holocaust and Genocide Studies     Hybrid Journal   (Followers: 28, SJR: 0.105, CiteScore: 0)
Human Communication Research     Hybrid Journal   (Followers: 13, SJR: 2.146, CiteScore: 3)
Human Molecular Genetics     Hybrid Journal   (Followers: 8, SJR: 3.555, CiteScore: 5)
Human Reproduction     Hybrid Journal   (Followers: 71, SJR: 2.643, CiteScore: 5)
Human Reproduction Open     Open Access  
Human Reproduction Update     Hybrid Journal   (Followers: 20, SJR: 5.317, CiteScore: 10)
Human Rights Law Review     Hybrid Journal   (Followers: 56, SJR: 0.756, CiteScore: 1)
ICES J. of Marine Science: J. du Conseil     Hybrid Journal   (Followers: 52, SJR: 1.591, CiteScore: 3)
ICSID Review     Hybrid Journal   (Followers: 10)
ILAR J.     Hybrid Journal   (Followers: 2, SJR: 1.732, CiteScore: 4)
IMA J. of Applied Mathematics     Hybrid Journal   (SJR: 0.679, CiteScore: 1)
IMA J. of Management Mathematics     Hybrid Journal   (SJR: 0.538, CiteScore: 1)
IMA J. of Mathematical Control and Information     Hybrid Journal   (Followers: 2, SJR: 0.496, CiteScore: 1)
IMA J. of Numerical Analysis - advance access     Hybrid Journal   (SJR: 1.987, CiteScore: 2)
Industrial and Corporate Change     Hybrid Journal   (Followers: 10, SJR: 1.792, CiteScore: 2)
Industrial Law J.     Hybrid Journal   (Followers: 35, SJR: 0.249, CiteScore: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 44, SJR: 2.511, CiteScore: 4)
Information and Inference     Free  
Integrative and Comparative Biology     Hybrid Journal   (Followers: 8, SJR: 1.319, CiteScore: 2)
Interacting with Computers     Hybrid Journal   (Followers: 11, SJR: 0.292, CiteScore: 1)
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7, SJR: 0.762, CiteScore: 1)
Intl. Affairs     Hybrid Journal   (Followers: 60, SJR: 1.505, CiteScore: 3)
Intl. Data Privacy Law     Hybrid Journal   (Followers: 25)
Intl. Health     Hybrid Journal   (Followers: 6, SJR: 0.851, CiteScore: 2)
Intl. Immunology     Hybrid Journal   (Followers: 3, SJR: 2.167, CiteScore: 4)
Intl. J. for Quality in Health Care     Hybrid Journal   (Followers: 37, SJR: 1.348, CiteScore: 2)
Intl. J. of Constitutional Law     Hybrid Journal   (Followers: 63, SJR: 0.601, CiteScore: 1)
Intl. J. of Epidemiology     Hybrid Journal   (Followers: 227, SJR: 3.969, CiteScore: 5)
Intl. J. of Law and Information Technology     Hybrid Journal   (Followers: 5, SJR: 0.202, CiteScore: 1)
Intl. J. of Law, Policy and the Family     Hybrid Journal   (Followers: 26, SJR: 0.223, CiteScore: 1)
Intl. J. of Lexicography     Hybrid Journal   (Followers: 9, SJR: 0.285, CiteScore: 1)
Intl. J. of Low-Carbon Technologies     Open Access   (Followers: 1, SJR: 0.403, CiteScore: 1)
Intl. J. of Neuropsychopharmacology     Open Access   (Followers: 3, SJR: 1.808, CiteScore: 4)
Intl. J. of Public Opinion Research     Hybrid Journal   (Followers: 9, SJR: 1.545, CiteScore: 1)
Intl. J. of Refugee Law     Hybrid Journal   (Followers: 35, SJR: 0.389, CiteScore: 1)
Intl. J. of Transitional Justice     Hybrid Journal   (Followers: 11, SJR: 0.724, CiteScore: 2)
Intl. Mathematics Research Notices     Hybrid Journal   (Followers: 1, SJR: 2.168, CiteScore: 1)
Intl. Political Sociology     Hybrid Journal   (Followers: 37, SJR: 1.465, CiteScore: 3)
Intl. Relations of the Asia-Pacific     Hybrid Journal   (Followers: 23, SJR: 0.401, CiteScore: 1)
Intl. Studies Perspectives     Hybrid Journal   (Followers: 9, SJR: 0.983, CiteScore: 1)
Intl. Studies Quarterly     Hybrid Journal   (Followers: 45, SJR: 2.581, CiteScore: 2)
Intl. Studies Review     Hybrid Journal   (Followers: 23, SJR: 1.201, CiteScore: 1)
ISLE: Interdisciplinary Studies in Literature and Environment     Hybrid Journal   (Followers: 2, SJR: 0.15, CiteScore: 0)
ITNOW     Hybrid Journal   (Followers: 1, SJR: 0.103, CiteScore: 0)
J. of African Economies     Hybrid Journal   (Followers: 15, SJR: 0.533, CiteScore: 1)
J. of American History     Hybrid Journal   (Followers: 46, SJR: 0.297, CiteScore: 1)
J. of Analytical Toxicology     Hybrid Journal   (Followers: 14, SJR: 1.065, CiteScore: 2)
J. of Antimicrobial Chemotherapy     Hybrid Journal   (Followers: 15, SJR: 2.419, CiteScore: 4)
J. of Antitrust Enforcement     Hybrid Journal   (Followers: 1)
J. of Applied Poultry Research     Hybrid Journal   (Followers: 4, SJR: 0.585, CiteScore: 1)
J. of Biochemistry     Hybrid Journal   (Followers: 40, SJR: 1.226, CiteScore: 2)
J. of Burn Care & Research     Hybrid Journal   (Followers: 9, SJR: 0.768, CiteScore: 2)
J. of Chromatographic Science     Hybrid Journal   (Followers: 18, SJR: 0.36, CiteScore: 1)
J. of Church and State     Hybrid Journal   (Followers: 11, SJR: 0.139, CiteScore: 0)
J. of Communication     Hybrid Journal   (Followers: 53, SJR: 4.411, CiteScore: 5)
J. of Competition Law and Economics     Hybrid Journal   (Followers: 35, SJR: 0.33, CiteScore: 0)
J. of Complex Networks     Hybrid Journal   (Followers: 2, SJR: 1.05, CiteScore: 4)
J. of Computer-Mediated Communication     Open Access   (Followers: 26, SJR: 2.961, CiteScore: 6)
J. of Conflict and Security Law     Hybrid Journal   (Followers: 12, SJR: 0.402, CiteScore: 0)
J. of Consumer Research     Full-text available via subscription   (Followers: 43, SJR: 5.856, CiteScore: 5)

        1 2 | Last   [Sort by number of followers]   [Restore default list]

Journal Cover
Annals of Oncology
Journal Prestige (SJR): 5.599
Citation Impact (citeScore): 9
Number of Followers: 42  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0923-7534 - ISSN (Online) 1569-8041
Published by Oxford University Press Homepage  [396 journals]
  • 100PRPS6 through the activation of NRF2 causes resistance to antiHER2
           drugs in HER2 amplified gastric cancer (GC) models
    • Authors: Gambardella V; Valiente F, Tarazona N, et al.
      Abstract: Background: Molecular mechanisms responsible for resistance to targeted agents are no longer clear and need to be clarified. Many pathways have been stressed to be responsible for acquired resistance in HER2 amplified GC, among them, PI3K/AKT/mTOR plays a relevant role. NRF2 was recently identified as a possible mechanism implicated in resistance to chemotherapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.039
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 101PInvolvement of miR-99a in resistance to chemotherapy in
           triple-negative breast cancer
    • Authors: Garrido-Cano I; Pattanayak B, Adam-Artigues A, et al.
      Abstract: Background: Breast cancer is the most prevalent type of cancer among women worldwide, and also the leading cause of women death in developed countries. Among the different breast cancer subtypes, triple-negative breast cancer is the most aggressive one. Those patients can be treated with cytotoxic therapies, but the most of them develop resistance against those drugs. Due to this reason, it is important to study new therapeutic approaches to increase the efficacy of chemotherapy. Herein, microRNAs have a major role in tumoral cell regulation as well as in drug resistance. Our aim was to determine which microRNAs are differentially expressed by MDA-MB-231 cells and MDA-MB-231 cells with acquired resistance to doxorubicin.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.040
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 102PMuscleblind-like 1 regulates epithelial to mesenchymal transition
           markers in triple-negative breast cancer
    • Authors: Adam Artigues A; Tormo E, Cerro-Herreros E, et al.
      Abstract: Background: Muscleblind-like 1 (MBNL1) has been deeply investigated because its implication in myotonic dystrophy. However, the role of RNA-binding proteins in breast cancer remains unknown. Recent findings suggest the role of MBNL1 as a suppressor of metastasis by stabilization of other genes in triple-negative breast cancer cell lines.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.041
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 104PStudy of toxicity of the conventional treatments in myeloproliferative
           neoplasms, based on the functional status of the RUNX1/CBF-BETA/P300/HIPK2
           complex
    • Authors: Lozano Asencio C; Cervera Vidal R, Climent Bataller J, et al.
      Abstract: Background: Myeloproliferative neoplasms (MPNs) are clonal hematological malignancies with an inherent tendency to progress to acute leukemia, after a variable period of time. Although the mechanisms involved in the disease transformation are still unclear, it´s known that transcription factor RUNX1 (AML1) is frequently deregulated in human leukemia, and recently, it has been described that the activity of RUNX1 together with CBF-β cofactor is regulated by the proteins p300 and HIPK2. In fact, HIPK2 phosphorylates both RUNX1 and p300, activating the whole transcriptional complex. Therefore, the study of the status of this complex seems to be interesting in order to understand the mechanisms involved in the leukemic transformation.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.042
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 105PGlycolytic enzymes lactate dehydrogenase A (LDHA) and
           phosphofructokinase P (PFKP) are good biomarkers of survival and potential
           therapeutic targets in cervical cancer
    • Authors: Bolaños L; Espinoza A, Alfaro A, et al.
      Abstract: Background: Cervical Cancer (CC) is the fourth most common cancer in women worldwide. Potential biomarkers in cancer can be identified by considering the changes in tumoral glycolysis. In this work, we investigated whether the expression of some glycolytic enzymes is associated with the overall and disease-free survival of patients with CC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.043
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 106PExperience of 22 patients with ROS mutated lung adenocarcinoma treated
           with crizotinib at a tertiary care center in India
    • Authors: Talreja V; Pande N.
      Abstract: Background: ROS1 hence became recognized as a distinct molecular target in NSCLC.Like ALK rearrangements ROS1 fusions are also found more in never smokers but define a distinct molecular subgroup with both rarely occurring together in same patient Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC .We report our experience in a tertiary cancer care centre in ROS-1 positive patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.044
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 107PComputational integrative analysis of identification of potential
           therapeutic genes and networks in breast cancer
    • Authors: Peer Mohammed M; Parthasarathy V.
      Abstract: Background: Cancer genomics research aims at investigation of biological pathways affected by mutations of these genes will help us to understand the determinants of cancer initiation, progression, and other biological functions. The sophisticated computational methods have been developed to facilitate the detection of cancer driver mutations and pathways. We made an attempt in this study to identify the potential candidate genes in the breast cancer carcinogenesis by computational integrative analysis. This approach is appropriated for identifying potentially useful diagnostic and prognostic biomarkers for therapeutic intervention of breast cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.045
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 108PThe effect of the seleno-L-methionin, sodium selenite and cadmium
           chloride on telomerase activity of chick embryo neural tube cells
    • Authors: Akhavan H; Hosseini-Asl S, Abbasgholizadeh H, et al.
      Abstract: Background: Telomerase is a ribonucleoprotein enzyme with reverse transcriptase activity, that more important in developmental processes including cell proliferation, differentiation, senescence and tumorigenesis. Selenium as a trace element for animals and human has been detected which can have anticancer properties, while cadmium (Cd) is a heavy metal in the natural environment and is very toxic. Purpose of this study was investigating the effects of Seleno-L-methionine, Sodium selenite and Cadmium chloride on the expression of telomerase activity in Chick embryo neural tube.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.046
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 109PPARP inhibitor (PARPi) monotherapy treatment in non-BRCA and/or
           non-serous gynaecological cancers
    • Authors: Ryan A; Cruz S, Miller R, et al.
      Abstract: Background: The vast majority of PARPi clinical trial experience in gynaecological cancer is for patients with platinum sensitive high grade serous ovarian carcinoma (HGSOC) and deleterious BRCA1/2 mutations. It is known that other homologous recombination deficiency (HRD) associated mutations exist eg RAD51, BRIP1 that can potentially sensitise to PARPi. Extremely limited clinical data exists on the use of PARPi in HGSOC with HRD mutations other than BRCA1/2; or in BRCA-mutated gynaecological cancers excluding HGSOC. We investigated the role of PARPi in a cohort of patients with non-BRCA and/or non-high grade serous (HGS) gynaecological cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.047
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 10PEGFR T790M mutation in treatment-naïve tumor samples: Low frequency,
           evidence for interaction with EGFR TKI-sensitizing mutations and lack of
           clear predictive value
    • Authors: Imyanitov E; Ivantsov A, Lavdovskaia E, et al.
      Abstract: Background: EGFR T790M mutation is associated with acquired resistance of lung cancer (LC) to first-generation TKIs. Several studies suggest that LCs often contain a small fraction of T790M-mutated cells even before the treatment, and the persistence of these mosaic clones renders poor tumor response to gefitinib or erlotinib.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 110TiPPREvalence of BRCA mutations and correlations with Demographic and
           clinical characteristICs in paTients with ovarian, fallopian tube or
           primary peritoneal cancer in Romania (PREDICT)
    • Authors: Cebotaru C; Stanculeanu D, Median D.
      Abstract: Background: The epidemiology of ovarian cancer in Romania is not well characterized and only few limited regional data are available. Moreover, the BRCA status in patients with homologous recombination-deficient tumorsis not known and no data about dominant founder mutations exist. BRCA1/2 are tumor suppression genes critical to DNA repair through homologous recombination in response to DNA damage. Around 13% of high-grade serous ovarian cancers is attributable to germline BRCA mutations.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.048
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 111OMechanism informs precision: In vivo determinants of response to
           anti-CTLA-4 antibodies
    • Authors: Furness A; Arce Vargas F, Litchfield K, et al.
      Abstract: Background: Anti-CTLA-4 antibodies (mAbs) display impressive activity in mouse models relative to human subjects, yet this is rarely acknowledged. Translational efforts to date have focused principally on identifying mechanisms of response and resistance in humans, with little reference to pre-clinical models. Through parallel analysis of mouse and human tumours, we sought to characterise respective in vivo determinants of response to anti-CTLA-4 mAbs.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy319
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 112OImmune classification of soft tissue sarcoma and its association with
           molecular characteristics, and clinical outcome
    • Authors: Petitprez F; de Reyniès A, Chen T, et al.
      Abstract: Background: Soft tissue sarcomas (STS) form a group of rare cancers which accounts for around 1% of tumors. In the era of immunotherapy, little is known on the clinical impact of the immune tumor microenvironment that may guide future immunotherapy trials.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy319.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 113PPlasminogen activator inhibitor-1 promotes immunosuppression in cancer
           by modulating immune component of tumor microenvironment
    • Authors: Yadav P; Kumar N, Kumar A, et al.
      Abstract: Background: Plasminogen activator inhibitor-1 (PAI-1) is corelated with inflammation and tumorigenesis. We investigated the role of PAI-1 in tumor regulating immune component of tumor microenvironment.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy319.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 114PComprehensive analysis for immune profiles of tumor microenvironment
           in lung adenocarcinomas: Prognostic effect of immunomodulatory molecules
    • Authors: Takamochi K; Hosoya M, Mogushi K, et al.
      Abstract: Background: Therapies targeting immune checkpoints have recently shown promising activity in patients with lung adenocarcinoma (LAD). T-cell activation is controlled by the balance of co-stimulatory molecules and co-inhibitory molecules (immune checkpoint molecules).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy319.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 115PGNMT negatively regulates MAPK pathway and suppresses the growth and
           metastasis of hepatocellular cancer cells
    • Authors: Jiang S; Jiang L, Fang J.
      Abstract: Background: Hepatocellular Carcinoma (HCC) has a generally poor prognosis, and molecular markers to improve early detection and predict outcomes are greatly needed. The aim of this study is to identify the recurrent genetic changes, elucidate their roles and discover new biomarkers for improving clinical management of HCC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy319.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 11PExpression of erythropoietin receptor variant forms is associated with
           lymphatic invasion and metastasis formation in breast cancer
    • Authors: Rakosy Z.
      Abstract: Background: Anemia not only impairs the quality of life of patients, but it leads to tumor hypoxia, resistance to therapy and reduces survival. Although recombinant Epo has revolutionized the treatment of anemia, clinical trials suggested a potential adverse effect of Epo on tumor recurrence and patient survival. Previously we identified altered EpoR mRNA transcripts in breast cancer cells lacking ligand binding domain exon 1-3 sequences in vitro. Our hypothesis is that altered expression of these proteins may be associated with unique clinicopathologic features.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 12PEvaluation of topoisomerase II, Ki-67 and P53 expression in non-muscle
           invasive urothelial carcinoma and their clinical significance
    • Authors: Elkhouly E; Alkady N, Soltan M.
      Abstract: Background: Trans-urethral resection of tumor (TURT) is the main treatment of non-muscle invasive urothelial carcinoma, but it is associated with high rate of recurrence and or progression, this arouses the need for adjuvant therapy. Topoisomerase II, KI67 and P53 are proliferation and cell cycle regulator markers that may predict tumor response to therapy. This study aimed to assess Top II, KI67 and P53 expression on clinical outcome and response to therapy of non-muscle invasive urothelial carcinoma.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 13PExpression of HER2-neu, SKP2 and HIF-1 and their role in predicting the
           response of muscle invasive urothelial carcinoma to bladder- preservation
           chemotherapy
    • Authors: Elkhouly E; Alkady N, Samir A.
      Abstract: Background: Cystectomy is the prime treatment of muscle-invasive urothelial carcinoma but it is associated with many complications and affects patients’ quality of life. Chemotherapy is an alternative modality, but it may not give the expected response. This arouses the need for markers that help to predict the response to chemotherapy. Her2-neu, Skp2 and HIF-1 regulate cell cycle progression, tumor adaptation to hypoxic environment and response to chemotherapy. This study aimed at evaluation of HER2-neu, SKP2 and HIF1 expression in muscle-invasive urothelial carcinoma and investigating the association between their expression and tumor response to chemotherapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 14PLINE-1 hypomethylation is a specific aberration in human hepatocellular
           carcinomas and correlates with shorter overall survival and
           CIMP-phenotypes
    • Authors: Anwar S; Vogel A, Lehmann U.
      Abstract: Background: Reactivation of interspersed repetitive sequences due to loss of methylation is associated with genome instability, one of the hallmarks in cancer. LINE-1 hypomethylation represents global methylation loss and has potential diagnostic and prognostic biomarkers in tumors. However, the correlation of LINE-1 hypomethylation with clinicopathological determinants and CpG island methylator phenotype (CIMP) in patients with liver tumors is not yet well defined.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.005
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 15PInvestigation of the combined action of cisplatin and
           6-phosphogluconate dehydrogenase inhibitor on pancreatic and lung cancer
           cell lines
    • Authors: Savenkova D; Minigulova L, Havrysh K, et al.
      Abstract: Background: One of the possible mechanisms of cisplatin resistance of tumors is a 6-phosphogluconate dehydrogenase (6-PGD) activation [R. Lin, 2015]. Investigation of the 6-PGD inhibition by selective small-molecule compound named Physcion is likely to be studied. However, there is a problem with selection of a less toxic solvent due to hydrophobicity of Physcion. This study was designed to optimize conditions and to study features of a combined action of cisplatin and Physcion on cell lines of pancreatic cancer AsPC-1 and lung carcinoma H1299.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.006
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 16PCD62L expression in chronic lymphocytic leukemia patients
    • Authors: Elkhouly E; Radwan W, Soliman M, et al.
      Abstract: Background: Chronic lymphocytic leukemia is the most common adult leukemia and often presents as early-stage disease. It could be stable for many years with no or minimal intervention. CD62L is a one of the selectin family of adhesion molecules which plays an important role in the trafficking/homing of lymphocytes to the lymph node. The objective of this study was to evaluate CD62L expression in chronic lymphocytic leukemia, and its effect on survival of malignant B-cells.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.007
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 17PTumor suppressor P53 gene codon 72 polymorphism and imatinib
           cytogenetic response in chronic myeloid leukemia
    • Authors: Elkhouly E; Khalifa K, Radwan W, et al.
      Abstract: Background: P53 polymorphism involves the substitution of an arginine for a proline at codon position 72. Many studies have investigated a genetic link between this variation and response to treatment in cancer. This study aimed to study p53 codon72 polymorphism in relation to cytogenetic response to imatinib treatment in patients with chronic myeloid leukemia (CML).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317.008
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 18ORepresentative sequencing: Profiling extreme tumor diversity
    • Authors: Litchfield K; Swanton C, Turajlic S.
      Abstract: Background: While next-generation sequencing (NGS) has been applied to thousands of solid tumors to date, there exists a fundamental undersampling bias inherent in current methodologies. This is caused by a biopsy input sample of fixed dimensions, which becomes grossly under-powered as tumor volume scales. Indeed, analysis of pan-cancer data reveals that current protocols sample on average only 1.5% of cancer cells, decreasing to 0.3% for stage IV tumors. Failure to address this bias risks undermining the clinical utility of genomic medicine in cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 19P100,000 Genomes Project: Cancer programme
    • Authors: Sosinsky A; Murugaesu N, Hamblin A, et al.
      Abstract: Background: The 100,000 Genomes Project aims to improve cancer care for NHS patients in the UK through personalised medicine. Our target is to return whole genome sequencing (WGS) results to clinicians in a clinically meaningful timescale to help with diagnosis and treatment choices for patient and in parallel to provide a research platform of genomic data linked to longitudinal clinical data. We demonstrate that WGA results for surgical resection or biopsy samples can be returned to clinicians within 2-3 weeks.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 1PApplication of liquid biopsies in metastatic gastrointestinal cancer to
           identify candidate therapeutic targets
    • Authors: Pérez L; Saiz López P, Sánchez-Escribano R, et al.
      Abstract: Background: Next-generation sequencing (NGS) of cell-free tumor DNA (ctDNA) has great potential for liquid biopsy in cancer diagnostics and to identify patients with actionable genomic alteration. This study, a prospective longitudinal study, focused in a cohort of metastatic cancer patients without standard effective active antineoplastic medical treatment options to establish the rate of patients with actionable genomic alteration and the rate of patients accessing medical treatment. The final objective was to determine the clinical performance based on non-invasive tumor sequencing.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 20PThe functional MDM4 genetic variant is associated with clinical outcome
           of lung adenocarcinoma patients with gefitinib treatment
    • Authors: Zhang N; Yang M, Zhang L, et al.
      Abstract: Background: As a mostly used epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), gefitinib significantly prolongs survival of lung adenocarcinoma patients with EGFR mutations. However, more than 10% of EGFR mutation-positive patients do not respond and a substantial fraction of responded patients progress after 8-12 months’ treatment. Identification of new biomarkers for EGFR-TKIs prognosis is vital. The objective of this study is to explore associations between MDM4 genetic variant and survival of lung adenocarcinoma patients treated with gefitinib.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 21PEvaluation of the TruSight Tumor 170 (TST170) assay and its value in
           clinical research
    • Authors: Heydt C; Pappesch R, Stecker K, et al.
      Abstract: Background: In recent years, parallel sequencing technologies have become integrated into daily clinical practice. Many institutions use amplicon-based approaches for the detection of somatic mutations. However, these assays do not routinely detect chromosomal aberrations or copy number changes (CNVs), which are still widely analysed by FISH and IHC, and struggle with de novo fusions. The development of new technologies to detect all therapeutically relevant genomic alterations in a single assay is an ongoing process. This study aimed to evaluate the TruSight Tumor 170 assay, a hybrid capture-based assay, for the simultaneous detection of somatic gene mutations, gene fusions and CNVs and its implementation into routine diagnostics.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 22PHead and neck squamous cell carcinoma organoids as a platform for
           personalized medicine
    • Authors: Driehuis E; Kolders S, Devriese L, et al.
      Abstract: Background: Organoids are 3D structures that recapitulate morphological, functional and genetic characteristics of the tissue of origin. Grown as organoids, primary cells can be kept in culture long-term without the requirement for immortalization or genetic alterations. In this study, we report the establishment of organoids derived of Head and Neck Squamous Cell Carcinomas (HNSCCs), which are tumors that arise from the squamous epithelium lining the oral cavity, pharynx and larynx. Overall five-year survival of patients diagnosed with this tumor is poor, and although many of the mutations detected in these tumors are therapeutically targetable, introduction of these treatment into the clinic has failed.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 23PIntegrating personalised medicine into the routine cancer diagnostic
           pathway in Manchester, UK
    • Authors: Henry J; Radford J.
      Abstract: Background: The 100,000 Genomes Project is a central element of NHS England’s Personalised Medicine Strategy, which aims to progress the move from a ‘one size fits all’ approach to patient treatment to more effective personalised therapies. The driver for this lies in the relative inefficacy of generic treatments; leading to at least 40% of patients receiving treatments that have no clinical benefit. This project is an NHS transformation initiative and aims to embed operational processes for Whole Genome Sequencing (WGS) of patient samples into routine clinical practice.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.005
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 24PClinical outcomes in patients with advanced NSCLC treated with targeted
           therapies, with actionable mutations identified by InVisionFirst ctDNA
           assay
    • Authors: Remon J; Mezquita L, Ortiz-Cuaran S, et al.
      Abstract: Background: ctDNA-based molecular profiling of advanced cancer patients with multi-gene next-generation sequencing (NGS) panels is rapidly gaining traction in clinical practice given faster results and more comprehensive stratification. However, clinical outcomes of patients with genomic alterations in plasma ctDNA by NGS panels remain poorly described. Here, we describe outcomes in advanced NSCLC patients with actionable alterations identified in plasma by InVisionFirst™-Lung.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.006
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 25PLeukocyte telomere length is associated with survival and drug
           resistance in lung adenocarcinoma patients treated with EGFR-TKIs
    • Authors: Yang M; Li J, Zhang N.
      Abstract: Background: Gefitinib is currently one of the mostly used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) recommended for treating non-small cell lung cancer. However, the factors that predict treatment prognosis and drug resistance to EGFR-TKIs remain elusive. The objective of this study is to exam the association between leukocyte relative telomere length (RTL) and prognosis or drug resistance of advanced lung adenocarcinoma to gefitinib treatment.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.007
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 26PAnalysis of changes in the markers of DNA methylation in the process of
           complex treatment in acute myeloid leukemia in children
    • Authors: Rudenko V; Kazakova S, Tanas A, et al.
      Abstract: Background: Acute myeloid leukemia (AML) is an "epigenetic" disease in the sense that the most common mutations in AML are somatic mutations in genes that regulate DNA methylation and demethylation. An aberrant DNA methylation distribution is a functional event in the process of leukemogenesis and a target of epigenetic therapy. Although epigenetic drugs (demethylating agents, histone deacetylase inhibitors) have been already used in the clinic for AML treatment, they do not provide point activation of the target region. Epigenetic variants of AML typical for children are particularly poorly understood.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.008
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 27PPREDMED®, a normalized expression signature of drug targets versus
           reference tissues aiming at generalizing treatment personalization
    • Authors: Verlingue L; Baranger M, Gianesini C, et al.
      Abstract: Background: The genomic landscape of tumors is highly heterogeneous. We aim at developing a tumor-agnostic and treatments-specific gene expression signature that could facilitate treatment personalization in the context of massive drug development.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.009
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 28PClinical impact of using a deep genomic profile in carcinoma of unknown
           origin
    • Authors: Fernandez Díaz A; Iranzo V, Calabuig Fariñas S, et al.
      Abstract: Background: Diagnosis and treatment of Cancer of Unknown Origin (CUP) continues to be a challenge. In the era of personalized medicine, genomic profile by Next-Generation-Sequencing (NGS) in addition to immunohistochemistry (IHC) tests may complement clinical features improving diagnosis and detecting targetable mutations. In the present study we have analysed the clinical utility of the OncoDEEP® CUP platform for tissue of origin assessment and genotyping in a cohort of CUP patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.010
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 29PImplementing molecular characterisation of prostate cancer tissue from
           patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE
           consortium
    • Authors: Grist E; Parry M, Mendes L, et al.
      Abstract: Background: STAMPEDE is a multi-arm, multi-stage (MAMS) platform protocol. It has recruited more than 10,000 patients since 2005. Hormone-sensitive metastatic or locally advanced prostate cancer patients starting androgen deprivation therapy (ADT) have been randomised between a number of experimental treatment pairings, including docetaxel or abiraterone, shown to improve overall survival. Funded by PCUK, the STRATOSPHERE consortium (Stratification for rational treatment-oncomarker pairings of STAMPEDE patients starting long-term hormone treatment) has established a framework to enable molecular analyses of archival tissue from these patients. We present the optimised work-flow and preliminary data on feasibility of next-generation sequencing (NGS) of FFPE archival samples.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.011
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 2PRETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for
           early high-risk HER2-positive breast cancer
    • Authors: Sabatier R; Garnier S, Carbuccia N, et al.
      Abstract: Background: Despite recent advances, early high-risk HER2-positive breast cancers (BC) have a risk of relapse close to 20%, with no validated prognostic biomarker. Circulating tumour DNA has been described to have a prognostic value for some early BC. Most published studies monitored mutations previously identified on tumour tissue. An alternate way to monitor plasma from patients with HER2-positive BC might be to look for ERBB2/HER2 amplification.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 30PClinical validation and utility of InVision ctDNA in advanced non-small
           cell lung cancer (NSCLC) patients
    • Authors: Remon J; Mezquita L, Planchard D, et al.
      Abstract: Background: Molecular profiling using liquid biopsy ctDNA is rapidly gaining traction in routine clinical practice. However, there has been variable degree of accuracy and performance published to date and lack of prospective data on clinical outcomes for patients with actionable genomic alterations in ctDNA biopsies. Here, we describe the clinical validation and utility of InVision platform (InvisionFirst™-Lung, InvisionSeq™-Lung) in a large prospective cohort of advanced NSCLC patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.012
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 31PMATCH-R development of preclinical models from patient with acquired
           resistance to targeted therapy
    • Authors: Bigot L; Deas O, Lang G, et al.
      Abstract: Background: Advances in molecular oncology and cancer genetics in the last 15 years have defined many of the key driving oncogenes in human cancer. Despite these successes it is now apparent that tumour cells adapt and develop acquired resistance to these targeted inhibitors so that disease progresses within 5-7 months.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.013
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 32PA novel 4-gene prognostic signature for hypermutated colorectal cancer
           (CRC)
    • Authors: Ge W; Cai W, Hu H.
      Abstract: Background: As previous studies have reported, hypermutated CRC account for approximately 15%-17% among all CRC. The proportion and number of patients with hypermutated CRC cannot be underrated. Additionally, hypermutated patients’ options of therapy are different, as they have a greater potential benefit from immunotherapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.014
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 33PA nomogram for the prediction of KRAS mutation in colorectal cancer
    • Authors: Xiang W; Dai W, Cai G.
      Abstract: Background: KRAS mutation status is crucial in treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in colorectal cancer (CRC). However, genetic testing is not available for some patients, either because tissue is limited and/or tests are not routinely offered. Hence, we aimed to build a nomogram based on clinical factors for the prediction of KRAS mutations in CRC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.015
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 34PEpigenomics paves a new way to assess potential toxicity and
           chemotherapeutic response of breast tumours to 5-fluorouracil
    • Authors: Strelnikov V; Ignatova E, Kekeeva T, et al.
      Abstract: Background: 5-fluorouracil (5-FU) is widely used in the therapy of solid tumors, including breast cancer (BC). Toxicity remains a major limitation in the clinical efficacy of 5-FU. Developed approximately 50 years ago, this competitive antagonist of uracil is still not exhaustively studied in terms of its mechanism of action, and the potential of molecular markers in predicting its efficacy and toxicity is not yet fully unravelled.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.016
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 35PDetection of ALK, RET, ROS1, NTRK1 and MET rearrangements and
           actionable mutations using next generation sequencing in patients with
           non-small cell lung cancer
    • Authors: Harlé A; Dietmaier W, Vogl I, et al.
      Abstract: Background: Targeted therapies have been developed this last decade and considerably improved PFS and OS of patients with NSCLC. Next-Generation Sequencing (NGS) is commonly used for the detection of actionable mutations in a panel of genes and FISH or IHC are the gold-standard assay for the detection of rearrangements of ALK, RET, ROS1, NTRK1 and MET. The aim of this study is to evaluate the suitability and reliability of NGS assay for the detection of rearrangements compared to the results obtained using FISH and IHC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.017
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 37PIgM anti-glycan antibodies in sera of colorectal cancer patients
    • Authors: Tikhonov A; Chernichenko M, Butvilovskaya V, et al.
      Abstract: Background: Colorectal cancer (CRC) is diagnosed too late due to the almost asymptomatic course of the disease. Many issues of diagnosis, prognosis and predicting of the treatment efficiency have not yet been resolved. The search and validation of new reliable molecular markers of CRC are still relevant. The aim of this study is to analyze the levels of anti-glycan antibodies in the sera of CRC patients and healthy donors.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.018
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 38PMicroarray based on comparative genomic hybridization reveals new
           recurrent genetic aberrations in acute myeloid leukemia
    • Authors: Prada-Arismendy J; Lopez-Rivera J, Carrillo Y, et al.
      Abstract: Background: Nearly half of acute myeloid leukemia (AML) patients show a normal karyotype, being the most heterogeneous group of patients. Because cytogenetic alterations are important prognostic factors, cryptic copy number alterations could explain some of the heterogeneity. Microarray-based comparative genomic hybridization (aCGH) has recently been used to study hematologic malignancies and has shown increased diagnostic yield, especially for cryptic findings.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.019
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 39PClinical interpretation of lung cancer molecular profiles using
           rule-based artificial intelligence
    • Authors: Tihanyi D; Hegedüs C, Várkondi E, et al.
      Abstract: Background: In the era of precision oncology, tumor genomic information is incorporated in clinical decision making to personalize treatment strategies; however, drawing clinically relevant conclusions from tumor molecular profiles are not straightforward if more druggable drivers or targets are identified, more drugs are linked to the same genetic alteration or evidence are conflicting. Here, we present the analysis of 704 lung cancer profiles using our proprietary algorithm and the personalized treatment protocols established by the rule-based artificial intelligence software, the RealTime Oncology Treatment Calculator.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.020
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 3PAutotaxin: A possible new biological marker of endometrial cancer
    • Authors: de Nola R; di Naro E, Schonauer L, et al.
      Abstract: Background: Endometrial cancer is the most common neoplasm of the female genital tract in Western Countries, with an incidence of 150000 new cases/year. Despite its high frequency, limited data are available about its molecular features. It is known that phospholipids play a key role in the cellular proliferation and dissemination in many human diseases. Some previous studies have demonstrated the importance of the lysophosphosphatidic acids’ (LPAs) metabolism and their signalling pathways in human endometrial cells. LPAs are produced via phospholipase A2 (PLA2) and phospholipase D (PLD), also known as autotaxin (ATX).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 40PSerum autoantibodies against tumor-associated antigen cyclin D1
           represent a potential biomarker of malignancy in well-differentiated
           thyroid tumors
    • Authors: Belousov P; Bogolyubova A, Efimova P, et al.
      Abstract: Background: Preoperative differential diagnosis of benign and malignant thyroid tumors remains a challenge in many cases, thus complicating the optimal planning of patients’ treatment. We have recently demonstrated the possibility of discrimination between benign and malignant thyroid lesions using serum autoantibody biomarkers. Here we further assessed whether a protein commonly overexpressed in malignant thyroid tumors may elicit an autoantibody response that may be used for serum-based preoperative differential diagnosis of thyroid nodular lesions.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.021
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 41PNext Generation Sequencing (NGS) and patient pathways: What is the
           impact on clinical decision'
    • Authors: Coquerelle S; Darlington M, Michel M, et al.
      Abstract: Background: Patient stratification, through the use of personalized medicine tools, is supposed to optimize patient care, reduce toxicities and increase the risk-benefit balance as well as decreasing healthcare costs. However, few studies have assessed the impact of Next Generation Sequencing (NGS) on clinical decision making. We evaluated whether information on mutational profiles modified clinical practice and care for patients with non-metastatic and metastatic cancer in an observational impact study.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.022
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 42PComparison of expression of microRNAs which regulate metastasis genes
           in breast cancer stem cells and primary breast cancer tissues
    • Authors: Rahimi M; Ebrahimi M, Alizadeh E.
      Abstract: Background: Recently in cancer research has shown that tumors are highly heterogeneous. Cancer developments are driven by specific cells-cancer stem cells (CSCs)-which are also responsible for metastases and drug resistance. Many studies have proved the significant role of miRNAs in controlling the Metastasis in CSCs. So, the present systematic analysis based on literature mining and bioinformatics approaches was performed to find the miRNAs in breast cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.023
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 43P‘Real world data’ of genomic sequencing for personalised
           therapy
    • Authors: Bergamino M; Vethencourt A, Stradella A, et al.
      Abstract: Background: AMPLICON deep sequencing to determine gene mutations (mut) and copy number alterations (CNA) helps to understand tumors' molecular biology and to personalize therapy. At Institut Català d’Oncologia l’Hospitalet it is used to find the best treatment options. We aim to analyze its efficiency.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.024
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 44PCorrelation between an automated functional assay that predicts
           targeted agent (TA) sensitivity and the tumor response of the sorafenib
           treatment evaluated within the MOST clinical trial
    • Authors: Tredan O; Zelichov O, Barbash Z, et al.
      Abstract: Background: MOST (My Own Specific Therapy) is a prospective, randomized, open-label, adaptive phase II trial conducted in patients (pts) with progressive solid tumors (any subtype) after at least one prior therapy in advanced setting. This trial aims to evaluate the clinical benefit of therapies targeting molecular alterations identified in the patient’s tumor. NovellusDx’ technology measures the functional impact of alterations including Variants of Uncertain Significance (VUS), and TA efficacy based on NGS findings.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.025
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 45PLessons from the routine tumor molecular profiling in Russia
    • Authors: Mileyko V; Rozhavskaya E, Veselovsky E, et al.
      Abstract: Background: Cost-effectiveness is one of the major limitations for tumor molecular profiling along with a small fraction of patients who can benefit from precision oncology approach. Our experience of providing an affordable molecular profiling (AMP) proves that focused biomarker panels and specific selection of patients for testing are the possible ways to overcome those obstacles.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.026
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 46PPotential prognostic markers for recurrence and survival in
           triple-negative breast cancer
    • Authors: Havrysh K; Mukhametshina G, Safina S, et al.
      Abstract: Background: Triple-negative breast cancer (TNBC) subtype is associated with an adverse outcome among BC patients. Since Overall Survival (OS) and recurrence prediction are significant to define suitable treatment strategies, an identification of prognostic markers for Disease-Free Survival (DFS) and OS is relevant. Here we aimed to estimate the effects of previously identified predictors of DNA-damaging therapy POLR2L, RAD50, SLC34A2, SMARCA5 and WDHD1 on OS and DFS in TNBC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.027
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 47PCharacterization of the different cell population in primary culture of
           breast tumor
    • Authors: Pattanayak B; Herrera G, Garrido-Cano I, et al.
      Abstract: Background: From decades’ immortal cells have been used as a model system to study the mechanism of cancer, drug resistance and explore the potential efficacy of the anticancer drugs. However, the numerous study has been suggested that studying the immortal cancer has a backdrop to represent the drug resistance and heterogeneity of the tumor in the patients. So, Primary tumor cultures currently begin to constitute the golden standard to study the lacking things, which has to apply to study the mechanism of resistance and personalized therapy including in breast tumor.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.028
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 48POncogenes and cancer-associated thrombosis: Is there a rationale for
           using molecular findings to assess thromboembolic risk in cancer
           patients'
    • Authors: Provenzano L; Platania M.
      Abstract: Background: Cancer-associated thrombosis (CAT) is one of the most threatening complications of cancer. Many questions are as yet unsolved in this field, from pathogenesis to clinical management. One of the most interesting issues is the role of oncogenes and oncosuppressors as link between carcinogenesis and CAT. There is much evidence on in vitro capacity of some oncogenes to enhance the clotting system, but less clinical evidence of association between cancer mutational status and risk of thromboembolic events. The aim of this study was to explore the relationship between mutational status of genes commonly analysed and risk of CAT.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.029
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 49TiPPersonalized neoadjuvant strategy in luminal A breast cancer to
           increase BCS rate (PLATO study)
    • Authors: Han W.
      Abstract: Background: The most important and well-established benefit of neoadjuvant therapy for breast cancer patients is increased breast conservation rate. However, in luminal A type breast cancer, the response to neoadjuvant chemotherapy (NCT) is not as good as other subtype of breast cancer, such as HER-2 or triple-negative breast cancer. In addition, with the advancement of multi gene assay tools for this subtype, adjuvant chemotherapy is not needed at all in significant proportion of this luminal A subtype. Through a selective neoadjuvant therapy, either chemotherapy or endocrine therapy using histopathologic markers and 70-gene assay (Mammaprint. Agendia inc.), we hypothesize that we could increase the breast conservation rate in lumnal A type breast cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy318.030
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 4PElevated plasma levels of hTERT mRNA and DNA in patients with gastric
           cancer in Northwest of Iran
    • Authors: Hosseini-Asl S; Akhavan H.
      Abstract: Background: Gastric cancer (GC) as the fourth common cancer over the world and responsible for the second cause of cancer-related deaths, has high incidence rate in Iran and especially in its North-Western province, Ardabil. In this study, the circulating hTERT mRNA and DNA were studied in patients affected with GC in Ardabil.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 50PA novel acetylated derivative of vitexin improves the immunogenic
           profile of breast cancer through tuning miR-20a/MICA Axis
    • Authors: Awad A; Youness R, Ibrahim M, et al.
      Abstract: Background: The activating immune ligand, MICA, acts as a “kill me” signal through the NKG2D receptor expressed on natural killer (NK) cells that are key players in the fight against breast cancer (BC). Shedding of MICA during BC progression acts as a formidable barrier against NK cells' immune-surveillance. Recently, miR-20a was found to mediate immune escape through repressing MICA levels on BC cells. However, targeting miR-20a/MICA using natural compounds has seldomly been investigated. Vitexin, a flavone C-glycoside, showed potent anticancer properties. It was reported that acetylation of glycosides increases their cytotoxic activity, with an unknown impact on immunogenicity. Our group has successfully isolated 3'-O-acetylvitexin from Ocimum basilicum which showed potent cytotoxic effects against colon cancer cells but has never been investigated in BC. Our aim is to unravel the role of the immunogenic miR-20a/MICA axis in BC patients and its regulation by vitexin and 3'-O-acetylvitexin.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 51PDNA damage ATR/Chk1 checkpoint signalling increases PD-L1 immune
           checkpoint activation and its implication for personalised combination
           therapy
    • Authors: Kumar N; Yadav P, Kumar A, et al.
      Abstract: Background: DNA double-strand break (DSB) is the most critical type of genotoxic stress. Clinical studies have revealed a link between genomic instability and response to anti-PD-1/PD-L1 therapy in cancer management. We investigated role of DBS repair and ATR/Chk1 DNA damage checkpoint in regulating PD-L1 expression and their use in therapy selection and study design.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 52PHedgehog pathway influence in the immune escape of tumor cells through
           PDL-1 modulation
    • Authors: Napolitano F; Di Mauro C, Pesapane A, et al.
      Abstract: Background: In recent years, immunotherapy has shown remarkable success in the treatment of several cancers. Masking PDL-1 on cancer cellular surface or PD1 on T-cells may increase the lymphocyte activity against the tumor. Intracellular regulation of PDL-1 may thus be a promising therapeutic strategy. However, the mechanism regulating PDL-1 expression remains unclear. Moreover, there are evidences supporting the idea that deregulation of Hedgehog (Hh) signalling has a role in immunity and inflammation. Therefore, we investigated whether activation of the Hh signalling contributes to regulate PDL-1 or PD1 expression and whether its pharmacological modulation affects the anti-tumor function of activated lymphocytes.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 53PmiR-4317, a promising player tuning the anti-tumor armamentarium
           against breast cancer
    • Authors: Youness R; Assal R, Abdelmotaal A, et al.
      Abstract: Background: Despite the clinical success of immune checkpoint inhibitors in Breast Cancer (BC), yet, the incidence of poor clinical responses in some patients had recently appeared in the clinics suggesting the emergence of drug resistance. Recent research has shifted towards innate immunity highlighting the promise of natural killer cells (NKs) as a more directed immunotherapeutic tool. Yet, cancer cells can still evade immune recognition by NK cells by shedding NKG2D ligands. MICA and ULBP2 are among the most de-regulated NKG2D ligands in BC patients. Tumor microenvironment is also capable of dampening NKs cytotoxicity. Therefore, researchers hypothesize that a potential anti-cancer agent should disturb such triad: halt the oncogenic activity of BC cells, improve its immunogenic profile and alleviates the immune-suppressive microenvironment. miRNAs are suggested as multifunctional players tuning the expression of several targets simultaneously. Finding a novel miRNA that could efficiently halt such triad of oncogenicity was our main goal. miR-4317 is a novel miRNA that has seldomly been analyzed in oncology. Thus, our aim was to investigate the impact of miR-4317 on BC oncogenic and immunogenic profiles.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 54PImpact of HPV DNA and p16 on radical chemo-radiotherapy response in
           oropharyngeal cancer patients
    • Authors: Yadav P; Kumar N, Beniwal S.
      Abstract: Background: Incidence of Oropharyngeal Cancer varies greatly worldwide showing an increasing trend. This increasing trend in epidemiology of Oropharyngeal Cancer has been attributed to the infection by human papillomavirus [HPV]. In this study we aimed to determine the impact of the presence of HPV DNA and p16 in oropharyngeal cancer on response to treatment and toxicity in patients receiving radical chemo-radiotherapy at regional cancer center.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 55PTP53 mutations as predictor of response and longer survival under
           immune checkpoint inhibitors in advanced non-small cell lung cancer
    • Authors: Assoun S; Theou-Anton N, Nguenang M, et al.
      Abstract: Background: Tumor mutational burden (TMB) correlates with response to immune checkpoint inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that TP53 mutations could reflect TMB and predict ICI benefit.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.005
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 56PQuantification BCL6 tissue expression using FISH and
           immunohistochemistry in diffuse large B-cell lymphoma by digital image
           analysis
    • Authors: Kushnarev V; Matyashina N.
      Abstract: Background: Computational method was developed to study how nucleus alterations would influence on cell cycle progression in cancer. It was verified that information retrieved from chromatin organisation areas and their heterogeneity can be used to infer nuclear morphological features. Diffuse large B-cell lymphoma (DBLC) is heterogeneous entity due to its morphologic alteration of cells. Numerous studies have attempted to further understand how nuclear morphology and expression antiapototic genes interfere on cell interaction and pathogenesis. Objective: To determine the immunohistochemical (bcl-6) molecular marker and morphological characteristics of nucleus (FISH probe BCL6) using digital pathology algorithm in patients with DBLC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.006
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 57TiP“PRIME Study": Searching for immune biomarkers in advanced
           castration resistant prostate cancer (CRPC) patients treated with standard
           therapy
    • Authors: Romero-Laorden N; Zapatero A, San Jose L, et al.
      Abstract: Background: CRPC is the lethal manifestation of the most frequent tumour in men. Despite of new target therapies emerged in last years patients will finally develop resistances that My be related to immune system alterations and it will lead to their death. Recent studies have shown that immunotherapy can be a critical therapeutic strategy. To identify how drugs that we use conventionally can modify the immune system at a microenvironment level is important to understand the biology of CRPC and the association with response/resistance to standard therapy, but also critical to the next future application of new immune therapeutic strategies in this setting.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.007
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 58TiPTRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma:
           Immune biomarker evaluation
    • Authors: Villa S; Pillai M, Graham D, et al.
      Abstract: Background: Metastatic renal-cell carcinoma (mRCC) is frequently fatal within months or a low number of years. Several life-extending drugs have been developed that can help alleviate symptoms, but treatment algorithms to arrive at which drugs, and in what order, are not yet defined. The immunotherapy checkpoint inhibitor nivolumab is the most commonly used second-line treatment, when first-line VEGF inhibition using a tyrosine kinase inhibitor (TKI) is no longer effective. However, in the pivotal trial, objective response rate to nivolumab in this setting was only 25%. Currently, there are no predictive biomarkers to identify patients with mRCC who will respond to nivolumab, nor is there data on the effect of first-line TKIs on patient’s likelihood of responding to second-line immunotherapy. Evaluating and correlating immune and molecular characteristics from blood and tumour may identify biomarkers that predict for immunotherapy response. Differences according to a particular TKI may also be identified; these variances could influence tolerance and response to second-line immunotherapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy315.008
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 59OPreliminary results on mechanisms of resistance to ALK inhibitors: A
           prospective cohort from the MATCH-R study
    • Authors: Recondo G; Mezquita L, Bigot L, et al.
      Abstract: Background: ALK tyrosine kinase inhibitors (TKIs) have shown to be effective in the treatment of patients with ALK rearranged NSCLC. The clinical benefit is eventually limited by the acquisition of resistance to ALK TKIs by tumor cells. The study of the biological mechanisms implied in tumor progression can provide the rational for therapeutic strategies to overcome resistance.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 5PCell-free circulating BRAF V600 mutations analysis by biochip-based
           assay and droplet digital PCR in melanoma patients
    • Authors: Emelyanova M; Telysheva E, Orlova K, et al.
      Abstract: Background: More than 50% of melanomas harbor BRAF V600 mutations and can be treated with targeted therapy. Circulating tumor DNA (ctDNA) harbors the same genetic alterations as a tumor origin. The analysis of ctDNA provides diagnostic and prognostic information before, during treatment and at progression. For detection mutations in ctDNA droplet digital PCR (ddPCR) most often are used. This method is very analytically sensitive, but expensive and time-consuming.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 60PTRIB3: A new transcriptional target gene of rapalogs, modulating their
           effects on splicing
    • Authors: Stefanovska B; Vicier C, Scott V, et al.
      Abstract: Background: The mTOR pathway has a key role in regulating cell growth and is altered in 70% of cancers. Rapalogs have become standard of care in patients with metastatic breast, kidney and neuroendocrine cancers. Nevertheless, tumor escape occurs after several months in most patients, highlighting the need to understand the mechanisms of action and resistance. Thus, we aim to identify new target genes of rapalogs that could be used as biomarkers to predict the treatment efficacy, or as therapeutic targets, to overcome resistance.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.001
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 61PChemotherapy after immunotherapy failure in patients with advanced
           gastrointestinal tumors
    • Authors: Baraibar Argota I; Martin Romano P, Sanmamed M, et al.
      Abstract: Background: First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and PFS. We have studied TGR and PFS before and after participation in phase I IT trials.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.002
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 62PIdentification of resistance mechanisms for EGFR-targeted therapy in
           head and neck squamous cell carcinoma: Combining whole-exome sequencing
           and tumour kinase profiling
    • Authors: de Pauw I; Wouters A, Van den Bossche J, et al.
      Abstract: Background: The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies such as cetuximab is a major clinical problem. This study aims to unravel resistance mechanisms by combining whole-exome sequencing (WES) and tumour kinase profiling. Based on the genetic and tumour kinase profile, new combination treatments can be designed to overcome therapy resistance.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.003
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 63PClinical impact of a comprehensive molecular approach in advanced
           gynecologic tumors
    • Authors: Lefort F; Chakiba C, Khalifa E, et al.
      Abstract: Background: Although knowledge of the molecular landscape in gynecologic tumors is increasing, the clinical impact of an extensive screening remains unclear. The aim of this monocentric study was to characterize molecular alterations in advanced gynecologic tumors, and to evaluate the clinical benefit of corresponding targeted agents.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.004
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 64PRegulating rs2278414 (G/A) disease-associated SNP in ZNF350 3’UTR by
           miR-150-5p: A step towards personalised therapy in breast cancer
    • Authors: Fouad E; Youness R, Assal R, et al.
      Abstract: Background: BRCA1/2 germline mutations accompanied by somatic mutations in p53 associated genes are associated with increased risk of developing breast cancer (BC). Genes acting upstream of p53, or participating in growth arrest following DNA damage such as the BRCA1-interacting protein, ZNF350, may modify the risk of BC in women with mutant BRCA1/2 through mediating BRCA1-induced transcriptional repression of several tumor suppressor genes. As a potential BC susceptibility gene, single nucleotide polymorphisms (SNPs) may influence transcriptional repression of ZNF350 target genes and individuals’ BC risk. Moreover, rs2278414 (G/A) SNP in ZNF350 3’UTR was associated with BC onset in BRCA1/2 carriers (“A” allele hazard ratio= 2.47). We aimed at regulating rs2278414 SNP in ZNF350 by miRNAs in BC as it has never been investigated in such context.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.005
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 65PFLYWCH1: A novel transcription factor with tumor suppressor activity
    • Authors: Almozyan S.
      Abstract: Background: Wnt/bβ-catenin-signaling pathway is the principal force of intestinal hemostasis and morphogenesis. Aberrant activity of this pathway is highly implicated in cancer development, particularly in colorectal cancer (CRC). Although Wnt/β-catenin pathway is a well-studied pathway, the precise molecular mechanisms involved in the nuclear interactions of β-catenin with DNA-binding transcription factors (other than TCF4) are still under debates. Human FLYWCH1 has been first characterized and identified in our lab as a novel transcription factor, which interacts with nuclear β-catenin and modulates its transcriptional activity (Muhammed et al., under publication).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.006
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 66PAdapting a prescreening program to match molecular alterations in over
           5,000 patients’ tumors with targeted agents and immunotherapies in early
           clinical trials over the last 8 years
    • Authors: Aguilar S; Vivancos A, Nuciforo P, et al.
      Abstract: Background: Since 2010, when the Molecular Prescreening Program (MPP) was established at VHIO, we have adapted the techniques and procedures to improve the identification of genomic alterations in tumors from patients (pts) eligible to Early Clinical Trials (ECTs). Here we report the clinical utility of our program given the evolving molecular testing landscape and trends in drug development.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.007
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 67PAssociation BRCA mutation status between BMN 673 (talazoparib), an oral
           PARP inhibitor, in triple-negative breast cancer
    • Authors: Guney Eskiler G; Cecener G, Egeli U, et al.
      Abstract: Background: The poly (ADP-ribose) polymerase (PARP) inhibitors appear to be a promising treatments strategy in BRCA-associated and/or sporadic triple-negative breast cancer (TNBC) due to the molecular heterogeneity of TNBC and the lack of defined molecular targets. However, there is no studies on the association between BMN 673 (talazoparib) efficacy, which is a novel and the most potent PARP1/2 inhibitor, and BRCA mutation status in TNBC. In the current study, we aimed to determine the cytotoxic and apoptotic effects of BMN 673 on TNBC cell lines according to BRCA mutational status.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.008
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 68PDifferences in expression profiling and biomarkers between histological
           colorectal carcinoma[s] subsets from the serrated pathway
    • Authors: Kot M; Garcia-Solano J, Turpin M, et al.
      Abstract: Background: Colorectal carcinomas (CRC) from the serrated route like serrated adenocarcinoma (SAC) and CC showing molecular features of microsatellite instability (hmMSI-H) share common features (preference for female gender, right side location, mucinous histology and altered CpG methylation patterns) but dramatically differ in terms of prognosis, development of immune response and treatment options. Despite this, to date no expression profiling comparison has been carried out to see which functions and genes may be responsible for such differences.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.009
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 69PMolecular profiling of tumour and ctDNA in a gastrointestinal cancer
           cohort at an academic cancer centre
    • Authors: Rack S; Brady G, Wallace A, et al.
      Abstract: Background: Circulating tumour DNA (ctDNA) can provide a minimally invasive liquid biopsy that may better capture tumour heterogeneity than archival biopsies. We report results of ctDNA and tumour molecular profiling from a gastrointestinal subset of patients recruited to the Tumour characterisation to Guide Experimental Targeted Therapy Trial (TARGET).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.010
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 6PNGS cfDNA data as a basis for the development of qPCR diagnostic systems
    • Authors: Mileyko V; Moiseenko D, Grinchenko A, et al.
      Abstract: Background: Circulating cell-free DNA (cfDNA) analysis can serve as a powerful diagnostic tool. However, most of the modern techniques used in oncology nowadays are based on expensive NGS procedures on the nuclear DNA. Here we propose a new approach for the development of cheap diagnostic tests based on cfDNA fragmentation profiles.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.005
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 70PEmerging role of FAT1 gene in the regulation of oncogenic miRNA
           221/222- 3p in glioma
    • Authors: Malik N; Chattopadhyay P, Sarkar C, et al.
      Abstract: Background: FAT1 is a transmembrane protein helps in adhesion. FAT1 gene is localized at chromosome 4q35.2 encoding a 506KDa. The role of FAT1 in tumors is not fully characterized. Few reports suggest it behaves as a tumor suppressive and few reported it as an oncogenic. miRNAs are noncoding RNAs which bind to the 3’UTR of target mRNA and repress their expression. miR-221-3p/222-3p has been reported to have oncogenic role and targets tumor suppressors (e.g. CDKN1B, PTEN, PUMA etc.) in many cancers including GBM. Here, we have investigated the role of FAT1 gene in the regulation of miRNAs in glioblastoma.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.011
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 71PRole of ATDC gene as a biomarker of doxorubicin response in
           triple-negative breast cancer
    • Authors: Cervera Vidal R; Lozano Asencio C, Tébar Martinez R, et al.
      Abstract: Background: Breast cancer is a complex and heterogeneous disease where the patients present the same symptoms and suffer the same disease, but due to different genetic reasons. Breast cancer recurrence is one of the biggest morbidity causes in patients that suffer the disease, and 15-20% of them will develop triple-negative breast cancer tumors (TN). The mortality of patients harbouring TN tumors is higher comparing with other tumor subtypes, in part, due to the difficulty of getting personalized treatments, where chemotherapy is the standard treatment. These data show the need to look for new drug strategy, where clinical, genetics and molecular data could be integred and compared, in order to predict more accurate treatment responses. Here we study the role of the gene ATDC, previously related with radioresistance, in TN breast cancer cell lines treated with Doxorubicin.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.012
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 72PGli promotes tumor progression and metastasis through regulating EMT in
           non–small-cell lung cancer
    • Authors: Jiang L; Jiang S, Wang L.
      Abstract: Background: Lung cancer is the leading causes of cancer-related deaths globally. The most frequent histologic type of lung cancer is non–small-cell lung cancer (NSCLC), accounting for approximate 85%. NSCLC is notoriously aggressive, and tumors often undergo epithelial-mesenchymal transition (EMT), a process required for invasion and metastasis. The components that control this process are thus promising therapeutic targets. This study examines the role of Sonic Hedgehog (SHh)/Gli pathway signaling in the regulation of EMT in NSCLC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.013
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 73PRole of miR-449 family on doxorubicin-based chemotherapy response in
           triple-negative breast cancer
    • Authors: Tormo Martin E; Adam-Artigues A, Garrido-Cano I, et al.
      Abstract: Background: microRNAs (miRNAs) emerge as a new step in the modulation of breast cancer response to treatment. The family of microRNAs 449 has been described as strong inducers of cell cycle arrest (including senescence) and apoptosis in distinct tumor types. The aim of this work is to analyse the miR-449 role in doxorubicin chemotherapy-based treatment of triple-negative breast cancer (TNBC).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.014
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 74PMutations in TSC1/TSC2 genes are prevalent in sporadic renal
           angiomyolipoma and insulinoma tumors, supporting their responsiveness to
           mTOR inhibitors
    • Authors: Anoshkin K; Vasilyev I, Mosyakova C, et al.
      Abstract: Background: The products of TSC1 and TSC2 genes, hamartin and tuberin respectively, form a complex that is the natural inhibitor of mammalian target of rapamycin (mTOR). Mutations in these genes are associated with such diseases as tuberous sclerosis (TS) and lymphangioleiomyomatosis, for which the main pharmacologic treatment at present is everolimus, the mTOR kinase inhibitor. Benign tumors like renal angiomyolipoma and pancreatic neuroendocrine tumors (PNET) can occur in tuberous sclerosis in 70% and 10% patients, respectively, but the overwhelming majority of them is sporadic. Despite the benign character, these tumors can be life-threatening. At the present time, the pathogenesis of sporadic renal angiomyolipoma (sRA) and PNETs is largely unknown but is growing as a research topic. Referring to cases of the tumors that occur in tuberous sclerosis, we assumed that TSC1 and TSC2 genes might play a key role in the development of sRA and PNETs.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.015
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 75PSynthetic lethal effects of BMN 673 loaded solid lipid nanoparticles on
           triple-negative breast cancer
    • Authors: Guney Eskiler G; Cecener G, Egeli U, et al.
      Abstract: Background: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) indicate the synthetically lethal effect in BRCA-defective breast cancers. BMN 673 has attracted considerable attention as the most potent PARPi with the highest PARP trapping efficiency. However, several mechanisms of PARPi resistance have been described in the literature. Solid lipid nanoparticles (SLNs) represent a promising new strategy to overcome resistance mechanisms due to unique features including their unique size and stability etc. In the present study, we aimed to determine a potential therapeutic effect of BMN 673 loaded SLNs formulation on homologous recombination (HR) in triple-negative breast cancer (TNBC).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.016
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 76PTargeting p63 upregulation may prevent the development of MAPK
           inhibitor resistance in melanoma
    • Authors: Borg T; Patel A, Bergamaschi D, et al.
      Abstract: Background: Melanoma progression is often characterized by mutations in the mitogen-activated protein kinase (MAPK) and phosphoinositol-3-kinase (PI3K) pathways. Understanding regulation of these pathways has led to the development of novel targeted therapies which show high response rates. However, many patients relapse with ensuing resistant disease. P63, a p53 homologue, carries a poorer prognosis when overexpressed. In keratinocytes, degradation could be regulated by two ubiquitin ligases, MDM2 and FBXW7. This project explored the expression of p63, MDM2 and FBXW7 in MAPK-inhibitor (MAPKi) sensitive and resistant melanoma cell lines.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.017
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 77PThe reduction of the expression of B-catenin and c-Myc is related to a
           better outcome in patients with AML
    • Authors: Cardona A; Prada-Arismendy J, Castillo E, et al.
      Abstract: Background: Acute myeloid leukemia (AML) is a malignant clonal disorder characterized by mutations affecting myeloid differentiation, gene expression, and epigenetic profiles. Although treatment strategy depends on a genetic profile-based risk, the accuracy of this stratification system is highly variable. Changes in gene expression profiles of signaling pathways involved in hematopoietic development, such as Wnt/B-catenin, may contribute to the transformation, development, and maintenance of leukemic cells, and could be related to the clinical outcome.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.018
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 78PLeukotriene B4 receptors as a therapeutic target for triple-negative
           breast cancer
    • Authors: Kalinkin A; Strelnikov V, Ignatova E, et al.
      Abstract: Background: Lipid mediators of inflammation, leukotrienes, are involved in tumour development and progression. Leukotriene B4 receptors 1 and 2 (LTB4R and LTB4R2) have been suggested to regulate tumor progression by promoting cell proliferation, survival, migration and metastasis. LTB4R2 was reported to increase invasiveness of breast cancer (BC) cells through IL-8 (interleukin-8) pathway. The inhibitors of leukotriene receptors have been suggested for use in anti-cancer therapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.019
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 79PWnt-signaling pathway in the cancer stem cells of glioblastoma
    • Authors: Bryukhovetskiy I; Shevchenko V, Khotimchenko Y.
      Abstract: Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor. The median survival time is 14,5 months. GMB resistance to treatment is associated with cellular population of cancer stem cells (CSCs). Wnt-signaling pathway is recognized as a strategically important proliferation mechanism for all stem cells. This study compares the expression levels of Wnt-signaling pathway proteins in CD133+ and CD133- cells in the common pool of GBM.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.020
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 7PPlasma ctDNA mutation anaysis for identification of initial and acquired
           resistance to HER2-targeted therapy in advanced gastric cancer patients
    • Authors: Gaye E; Bellosillo Paricio B, Visa L, et al.
      Abstract: Background: Primary or acquired resistance to trastuzumab limits targeted treatment efficacy. Circulating tumor (ct)DNA is a potential surrogate to tissue that overcomes intratumoral heterogeneity with a minimal invasive approach. We assessed genomic alterations (GAs) of ctDNA and demonstrated molecular changes during trastuzumab therapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.006
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 80PTRK wild-type and fusion protein expression in solid tumors:
           Characterization by immunohistochemistry and in situ hybridization
    • Authors: Feng J; Ebata K, Hansen F, et al.
      Abstract: Background: Neurotrophic tyrosine receptor kinases (NTRK1-3) are a gene family encoding kinases involved in development and maturation of the central and peripheral nervous system. In cancer, fusion of one of these genes with various upstream partners leads to aberrant protein expression and unchecked proliferation. Identification of tumors driven by TRK fusions is clinically relevant because they can be targeted by highly selective small molecule inhibitors. Pan-TRK immunohistochemical (IHC) staining for aberrant expression of TRK proteins may be an important approach to identify tumors with TRK fusions when followed by confirmation. We describe the expression, both wild-type (WT) and fusion, of TRK proteins in 19 solid tumors.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.021
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 81PEPHA2/MAPK pathway confers acquired resistance of afatinib in gastric
           cancer
    • Authors: Chen Z; Liu Z, Gao J, et al.
      Abstract: Background: We explored antitumor activity of afatinib in vitro and in vivo in gastric cancer (GC). In addition, underlying antitumor and acquired resistant mechanisms of afatinib were also investigated.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.022
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 82PThe clinical impact of miRNA34a and P53 gene expression in colon cancer
    • Authors: Gohar S; Badr E, Assar M, et al.
      Abstract: Background: The potential role of miRNA34a gene expression as biomarkers of colorectal cancer is not well known , the current study aimed to evaluate its diagnostic and prognostic value and its relationship with P53 gene expression, fate, stage, metastasis and overall survival of colorectal cancer.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.023
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 83PComparing clonality between components of combined hepatocellular
           carcinoma and cholangiocarcinoma by targeted sequencing
    • Authors: Yoon N; Jeon J.
      Abstract: Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a very rare tumor. It has two different components (hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC)) in a single mass. Although several studies have determined genetic characteristics of cHCC-CC, Next-generation sequencing (NGS) data for comparing clonality of cHCC-CC are currently unavailable.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.024
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 85PThe role of topoisomerase II-α (TOPO IIA) as a predictive factor for
           response to neoadjuvant anthracycline-based chemotherapy in locally
           advanced breast cancer
    • Authors: Gamea M.
      Abstract: Background: Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate whether topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.025
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 86PDoes the long noncoding RNA HULC act as a sponge or as a downstream
           target for miR-186 in hepatocellular carcinoma'
    • Authors: Habashy D; Hosny K, Esmat G, et al.
      Abstract: Background: The long noncoding RNA (lncRNA) highly up-regulated in liver cancer (HULC) was identified as an oncogenic noncoding RNA that contributed to hepatocellular carcinoma (HCC) progression. Generally, lncRNAs have been shown to act as a sponge for microRNAs, hindering them from performing their actions. Recent study has shown that HULC sequester miR-186, meanwhile its expression was repressed by it. Our bioinformatics revealed that miR-186 targets HULC and the insulin-like growth factor 2-mRNA-binding protein-1 (IGF2BP1) which was shown to degrade HULC and to stabilize IGF1R in HCC. Therefore, we aimed at investigating the impact of miR-186 on IGF2BP1 and hence on HULC in liver cancer in attempt to unravel the underlying mechanism by which HULC enhances hepatocarcinogenesis.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.026
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 87PMir-506-3p synergistically represses breast cancer progression through
           altering cell cycle regulators
    • Authors: Saad El Din G; Youness R, Assal R, et al.
      Abstract: Background: Mounting evidence demonstrated the potential of miR-506-3p to be employed in the diagnosis and treatment of a wide range of human malignancies due to its differential expression pattern and distinct biological roles. Despite the pivotal tumor suppressor role miR-506-3p plays in breast cancer (BC), it is frequently downregulated. Moreover, its role in governing cell cycle progression was not extensively studied in BC. Myc, E2F and Rb proteins are key players in cell cycle regulation. In BC, the CDK-RB-E2F axis is extensively deregulated by several genetic mutations. Additionally, the potent proto-oncogene Myc is highly expressed in BC. Thus, we aimed at uncovering the role miR-506-3p plays in cell cycle regulation in BC.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.027
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 88PCrosstalk between hesperetin and miR-486-5p in triple-negative breast
           cancer (TNBC): An approach towards precision medicine
    • Authors: Abdallah R; Youness R, El Meckawy N, et al.
      Abstract: Background: Hesperetin an aglycone extracted from citrus fruits, acts as a novel therapeutic agent in breast cancer (BC). TNBC patients showed the most heterogeneous molecular profiles portrayed with inferior overall survival. This highlights the emerging need of precision medicine to unravel the inter-wined molecular circuits in TNBC patients. Our group has uncovered the tumor suppressor activity of miR-486-5p in liver cancer and BC. However, its role in tuning the metastatic behaviour of TNBC cells remains to be unveiled. This study aims at investigating the interplay of hesperitin and miR-486-5p as a novel therapeutic approach towards achieving a personalized treatment code for TNBC patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.028
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 8TiPCirculating tumour DNA as an early marker of recurrence and treatment
           efficacy in ovarian carcinoma, the CIDOC study
    • Authors: Sabatier R; Pomel C, Colombo P, et al.
      Abstract: Background: Ovarian carcinomas (OvC) are the fifth cause of death by cancer in women and display a very poor prognosis (5-y survival of 30%). Genomic alterations involved in OvC can be identified only by invasive tumour sampling using surgical procedures or guided-biopsies, and are thus not easily monitored during treatment and follow-up. In the last years, circulating tumour DNA (ctDNA) has been explored in many fields for several tumour localizations. Concerning OvC, ctDNA detection is feasible and its correlation with response to treatment has been mentioned for relapsing disease. However, the capacity of ctDNA to be an early marker of relapse has not been described.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy316.007
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 90PPrognostic value of immune gene’s expression in head and neck
           squamous cell carcinoma patients
    • Authors: Lecerf C; Kamal M, Vacher S, et al.
      Abstract: Background: Nivolumab and pembrolizumab that target the PD-1 immune check point have recently been approved in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients who have failed platinum therapy. We aimed to evaluate the prognostic value of selected immune genes’ expression in a retrospective analysis of 96 untreated HNSCC patients.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.029
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 91PA major response to carboplatin in a metastatic triple-negative breast
           cancer patient with somatic mutation of BRCA1 and RAD51B: When
           chemotherapy meets precision medicine
    • Authors: Seguin L; Chaffanet M, Sabatier R, et al.
      Abstract: Background: Recent clinical data indicate a higher pathological complete response rate when platinum is added to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC), and favorable outcomes have also been observed in metastatic TNBC patients treated with platinum-based regimen. BC associated with germline BRCA mutations display DNA double-strand break repair defects, which are thought to render them particularly sensitive to DNA repair targeting drugs such as PARP inhibitors and/or platinum analogs. In addition, BRCA1/2 genes promoter methylation, somatic mutation, as well as other genomic alterations in DNA repair genes may also drive homologous recombination-deficiency (HRD) and the so-called “BRCAness” phenotype. Yet, their association with sensitivity to platinum derivatives or PARP inhibitors in BC remains discussed.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.030
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 92PNext-generation sequencing reveals high intra-individual molecular
           concordance between primary head and neck tumors and matched local or
           distant recurrences
    • Authors: Martin N; Ebran-Bendahhou N, Boyer J, et al.
      Abstract: Background: Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is an uncurable disease and is responsible of 4 000 deaths every year in France. Targeted therapies improve outcomes in several types of cancer and lead to development of the prescription of drugs according to the molecular features of the tumor, called “precision medicine”. The need to perform recent biopsy to perform those molecular analyses is a critical restriction and limits inclusion of patients into precision medicine programs.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.031
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 93PDecreasing telomerase activity of adenocarcinoma cancer cell line (AGS)
           is associated with different concentrations of sodium selenite and cadmium
           chloride and selenium l methionine
    • Authors: Hosseini-Asl S; Fazabakhsh A, Sagha M.
      Abstract: Background: Selenium (Se) has been recognized as an essential element for animals and humans. In the late 1960s, it was first suggested that selenium might have anti-cancer properties. Selenium controls apoptosis in cell cycle. Cadmium (Cd) is a widely used heavy metal that affects human health through occupational and environmental exposure and has been reported as a cause of cancers such as lung, prostate and kidney. The previous studies on Ovarian and breast cancer have shown that cadmium increases telomerase activity and expression level of hTERT. In the present study, we find out the effect of sodium selenite and selenium l methionine and cadmium chloride on telomerase activity in adenocarcinoma cancer cell line (AGS).
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.032
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 94PMolecular testing of gliomas
    • Authors: Konvalinka D; Mech R, Urbanovska I, et al.
      Abstract: Background: Gliomas are the most frequent CNS primary tumours, which account for up to 80 % of brain malignancies. Important diagnostic and prognostic factor, and recently significant WHO glioma classification marker as well, is mutational status of IDH1/2 genes. Moreover, search for another markers with predictive character is needed. Methylation status of MGMT gene promoter is one of relevant predictive markers, connected with therapeutic response to chemotherapy.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.033
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 95PFirst report of ZNF518B gene expression as a prognostic factor in
           colorectal cancer development: Role in tissue invasiveness
    • Authors: Valiente F; Riffo-Campos A, Cervantes A, et al.
      Abstract: Background: Colorectal cancer (CRC) represents a relevant public health problem. Despite new therapeutic advances, prognosis of patients diagnosed with advanced disease is still poor. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. We describe here the possible role of ZNF518B, a gene not yet well characterised, on tissue invasion. Human ZNF518B gene, which encodes a putative, zinc finger-containing transcription factor, yields two major alternative splicing isoforms.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.034
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 96PERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC)
    • Authors: Venturelli M; Toss A, Piacentini F, et al.
      Abstract: Background: An increasing number of molecularly targeted drugs are now available and, for some of these therapies, predictive biomarkers have already been identified. In particular, mutations in ERBB2 might represent an alternative mechanism for HER2 activation. They occur more frequently in HER2-negative (HER2-) tumors and seem to be good target for HER2 therapy. Furthermore, PI3KCA mutations showed to predict sensitivity to Fulvestrant, Buparlisib, Taselisib and resistance to Lapatinib. We evaluated the incidence of ERBB2 and PI3KCA mutations in 14 hormone receptor (HR)-positive BC and in their matched endocrine-resistant recurrences.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.035
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 97PRANK expression predicts long term outcome in early luminal breast
           cancer
    • Authors: Kassem L; Clézardin P, Treilleux I.
      Abstract: Background: Drugs targeting the RANK/RANK-ligand pathway may improve the outcome in early breast cancer, mainly due to prevention of bone metastasis. We aimed at exploring the value of RANK expression in primary breast cancer samples and its impact on the incidence of bone and visceral metastases.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.036
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 98PCustomized or randomized trials for relapsed refractory pediatric
           Burkitt lymphomas' A retrospective analysis of two clinical cases with
           comprehensive molecular profiling: Possible explanation for different
           treatment outcomes after similar targeted therapies
    • Authors: Polaskova K; Martincekova A, Krenova Z, et al.
      Abstract: Background: Current standard chemoimmunotherapy achieves survival in almost 95% children with mature B-NHL. However, children with relapses still carry very poor prognosis.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.037
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 99PMolecular treatment stratification in second-line treatment of
           pancreatic adenocarcinoma: PePaCaKa-001
    • Authors: Kordes M; Löhr M, Malgerud L, et al.
      Abstract: Background: Pancreatic cancer (PDAC) is highly resistant to cytotoxic chemotherapy and several trials of molecularly targeted drugs have failed. However, some tumors with specific somatic mutations respond to targeted therapy and patients might profit from treatment stratified by genetic biomarker profiles.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy314.038
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • 9ONovel mechanism of platinum resistance: Rapid selection of pre-existing
           BRCA1-proficient tumor cells during neoadjuvant chemotherapy (NACT) for
           ovarian cancer (OC) in BRCA1 germ-line mutation carriers
    • Authors: Imyanitov E; Savonevich E, Ivantsov A, et al.
      Abstract: Background: Cancers arising in BRCA1 mutation carriers are highly sensitive to cisplatin due to somatic inactivation of the wild-type BRCA1 allele. Accordingly, BRCA1-driven OCs usually respond well to NACT and therefore almost always undergo complete cytoreduction. However, despite this seemingly effective treatment and continuation of platinum therapy in the adjuvant setting, almost all BRCA1-associated OCs inevitably relapse.
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy317
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • Drug Index
    • Abstract: Abiraterone: 29P, 57TiP
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy324
      Issue No: Vol. 29, No. suppl_6 (2018)
       
  • Translational Research Index
    • Abstract: ABCG2: 99P
      PubDate: Sun, 16 Sep 2018 00:00:00 GMT
      DOI: 10.1093/annonc/mdy325
      Issue No: Vol. 29, No. suppl_6 (2018)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.161.71.87
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-